PE20050013A1 - Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c - Google Patents
Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis cInfo
- Publication number
- PE20050013A1 PE20050013A1 PE2004000340A PE2004000340A PE20050013A1 PE 20050013 A1 PE20050013 A1 PE 20050013A1 PE 2004000340 A PE2004000340 A PE 2004000340A PE 2004000340 A PE2004000340 A PE 2004000340A PE 20050013 A1 PE20050013 A1 PE 20050013A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- protease
- cycloalkyl
- halogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: (a) UN COMPUESTO DERIVADO DE LA FORMULA I, O UNO DE SUS TAUTOMEROS, EN DONDE L1 Y L2 SON, INDEPENDIENTEMENTE ENTRE SI, HALOGENO, ALQUILO C1-C4, ALQUILO-O C1-C4, ENTRE OTROS; ------- INDICA UN ENLACE OPCIONAL QUE FORMA UN DOBLE ENLACE ENTRE LAS POSICIONES 13 Y 14, R1 ES H, HALOGENO, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R2 ES H, HALOGENO, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R3 ES R9-O o R9-NH; R4 ES H O DE 1-3 SUSTITUYENTES EN CUALQUIER ATOMO DE CARBONO DISPONIBLE EN LAS POSICIONES 8, 9, 10, 11, 12, 13 o 14 SELECCIONADO ENTRE ALQUILO C1-C6, HALOGENOALQUILO C1-C6, ALCOXI C1-C6, HIDROXI, ENTRE OTROS; R9 ES ALQUILO C1-C6 o CICLOALQUILO C3-C6; (b) DE 1% A 10% EN PESO DE UNA AMINA O MEZCLA DE AMINAS FARMACEUTICAMENTE ACEPTABLES; (c) DE 0,1% A 10% EN PESO DE UNA BASE O MEZCLA DE BASES FARMACEUTICAMENTE ACEPTABLES; (d) UNO O MAS ACEITES FARMACEUTICAMENTE ACEPTABLES; (e) OPCIONALMENTE UNO O MAS DISOLVENTES HIDROFILOS FARMACEUTICAMENTE ACEPTABLES; (f) OPCIONALMENTE UNO O MAS POLIMEROS FARMACEUTICAMENTE ACEPTABLES; (g) OPCIONALMENTE UNO O MAS TENSIOACTIVOS FARMACEUTICAMENTE ACEPTABLES. LOS COMPUESTOS DERIVADOS DE LA FORMULA I SON INHIBIDORES DE LA PROTEASA DEL VIRUS DE LA HEPATITIS C, ESPECIALMENTE DE LA SERINA-PROTEASA NS3 DEL VHC Y SON UTILES PARA TRATAR UNA INFECCION POR EL VHC
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45976503P | 2003-04-02 | 2003-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050013A1 true PE20050013A1 (es) | 2005-03-01 |
Family
ID=33310709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000340A PE20050013A1 (es) | 2003-04-02 | 2004-03-31 | Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c |
Country Status (24)
Country | Link |
---|---|
US (1) | US7157424B2 (es) |
EP (1) | EP1613353A1 (es) |
JP (1) | JP2006522017A (es) |
KR (1) | KR20050108420A (es) |
CN (1) | CN100363055C (es) |
AR (1) | AR043795A1 (es) |
AU (1) | AU2004231538A1 (es) |
BR (1) | BRPI0409068A (es) |
CA (1) | CA2520886A1 (es) |
CO (1) | CO5640152A2 (es) |
EA (1) | EA010013B1 (es) |
EC (1) | ECSP056065A (es) |
HK (1) | HK1091130A1 (es) |
HR (1) | HRP20050871A2 (es) |
MX (1) | MXPA05010338A (es) |
NO (1) | NO20055057L (es) |
NZ (1) | NZ543250A (es) |
PE (1) | PE20050013A1 (es) |
RS (1) | RS20050741A (es) |
TW (1) | TW200505484A (es) |
UA (1) | UA81028C2 (es) |
UY (1) | UY28250A1 (es) |
WO (1) | WO2004093915A1 (es) |
ZA (1) | ZA200506019B (es) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
PE20050431A1 (es) * | 2003-09-22 | 2005-07-19 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
EP1730167B1 (en) * | 2004-01-21 | 2011-01-12 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
BRPI0506945A (pt) | 2004-01-30 | 2007-06-12 | Medivir Ab | inibidores de serina protease ns-3 de hcv |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2006242475B2 (en) * | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7470664B2 (en) * | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
NZ565059A (en) | 2005-07-25 | 2011-08-26 | Intermune Inc | Novel macrocyclic inhibitors of hepatitus C virus replication |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
US8278322B2 (en) * | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
JP2009511595A (ja) * | 2005-10-11 | 2009-03-19 | インターミューン・インコーポレーテッド | C型肝炎ウイルスの複製を阻害する化合物および方法 |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
GB0609492D0 (en) * | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US20070281884A1 (en) * | 2006-06-06 | 2007-12-06 | Ying Sun | Macrocyclic oximyl hepatitis C protease inhibitors |
US8268776B2 (en) | 2006-06-06 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US9526769B2 (en) | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
EP2079479B1 (en) | 2006-10-24 | 2014-11-26 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
CA2667266C (en) | 2006-10-24 | 2015-11-24 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
JP2010507656A (ja) * | 2006-10-24 | 2010-03-11 | メルク エンド カムパニー インコーポレーテッド | Hcvns3プロテアーゼ阻害剤 |
ES2444575T3 (es) * | 2006-10-27 | 2014-02-25 | Merck Sharp & Dohme Corp. | Inhibidores de la proteasa NS3 del VHC |
MX2009004556A (es) * | 2006-10-27 | 2009-07-10 | Merck & Co Inc | Inhibidores de la proteasa ns3 del hcv. |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0625349D0 (en) * | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
WO2008075103A1 (en) * | 2006-12-20 | 2008-06-26 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
EP2177523A1 (en) * | 2007-05-03 | 2010-04-21 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
CL2008001381A1 (es) * | 2007-05-10 | 2008-11-03 | Intermune Inc Y Array Biopharma Inc | Compuestos derivados de tripeptidos que contienen heterociclos nitrogenados; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una infeccion de hepatitis c o vih. |
EP2178885A1 (en) | 2007-07-17 | 2010-04-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
US8927569B2 (en) | 2007-07-19 | 2015-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as antiviral agents |
GB2451811A (en) * | 2007-08-09 | 2009-02-18 | Ems Sa | Delivery composition for solubilising water-insoluble pharmaceutical active ingredients |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
US8263549B2 (en) | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
US8030307B2 (en) | 2007-11-29 | 2011-10-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease |
CA2708047A1 (en) | 2007-12-06 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Process for making macrocyclic oximyl hepatitis c protease inhibitors |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
WO2009108507A1 (en) | 2008-02-25 | 2009-09-03 | Merck & Co., Inc. | Therapeutic compounds |
AP2010005416A0 (en) | 2008-04-15 | 2010-10-31 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication. |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2720850A1 (en) * | 2008-04-28 | 2009-11-05 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
DE102008022520A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044023B2 (en) | 2008-05-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
PT2540350E (pt) * | 2008-07-22 | 2014-08-27 | Merck Sharp & Dohme | Combinações de um composto de quinoxalina macrocílico o qual é um inibidor da protease ns3 do hcv com outros agentes do hcv |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
BRPI0923184A2 (pt) | 2008-12-19 | 2019-09-24 | Gilead Sciences Inc | inibidores de hcv ns3 protease |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
PT2451438E (pt) | 2009-07-07 | 2014-03-26 | Boehringer Ingelheim Int | Composição farmacêutica para um inibidor de protease viral da hepatite c |
EP2459582B1 (en) | 2009-07-30 | 2015-05-27 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
WO2011112558A2 (en) * | 2010-03-10 | 2011-09-15 | Abbott Laboratories | Solid compositions |
CA2819894A1 (en) * | 2010-12-16 | 2012-06-21 | Abbvie Inc. | Anti-viral compounds |
SG191759A1 (en) | 2010-12-30 | 2013-08-30 | Enanta Pharm Inc | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
US20120213855A1 (en) * | 2011-02-17 | 2012-08-23 | Cima Labs Inc. | Dosage forms for weakly ionizable compounds |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2723337A1 (en) | 2011-06-23 | 2014-04-30 | Panmed Ltd. | Treatment of hepatitis c virus |
EP2780026B1 (en) | 2011-11-15 | 2019-10-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
WO2014058794A1 (en) | 2012-10-08 | 2014-04-17 | Abbvie Inc. | Compounds useful for making hcv protease inhibitors |
JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
CN103965286B (zh) * | 2014-04-22 | 2017-11-03 | 南京安赛莱医药科技有限公司 | 丙型肝炎病毒(hcv)ns3蛋白酶抑制剂 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69808463T2 (de) * | 1997-07-29 | 2003-06-26 | Upjohn Co | Selbstemulgierende formulierung enthaltend saure lipophile verbindungen |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
PE20050431A1 (es) * | 2003-09-22 | 2005-07-19 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c |
-
2004
- 2004-03-23 NZ NZ543250A patent/NZ543250A/en unknown
- 2004-03-23 BR BRPI0409068-3A patent/BRPI0409068A/pt not_active IP Right Cessation
- 2004-03-23 CA CA002520886A patent/CA2520886A1/en not_active Abandoned
- 2004-03-23 UA UAA200510334A patent/UA81028C2/uk unknown
- 2004-03-23 WO PCT/US2004/008837 patent/WO2004093915A1/en active Application Filing
- 2004-03-23 US US10/807,023 patent/US7157424B2/en active Active
- 2004-03-23 KR KR1020057018703A patent/KR20050108420A/ko not_active Application Discontinuation
- 2004-03-23 EA EA200501532A patent/EA010013B1/ru not_active IP Right Cessation
- 2004-03-23 EP EP04759731A patent/EP1613353A1/en not_active Withdrawn
- 2004-03-23 AU AU2004231538A patent/AU2004231538A1/en not_active Abandoned
- 2004-03-23 JP JP2006501244A patent/JP2006522017A/ja active Pending
- 2004-03-23 CN CNB2004800087739A patent/CN100363055C/zh not_active Expired - Fee Related
- 2004-03-23 MX MXPA05010338A patent/MXPA05010338A/es active IP Right Grant
- 2004-03-23 RS YUP-2005/0741A patent/RS20050741A/sr unknown
- 2004-03-31 TW TW093108968A patent/TW200505484A/zh unknown
- 2004-03-31 UY UY28250A patent/UY28250A1/es not_active Application Discontinuation
- 2004-03-31 AR ARP040101067A patent/AR043795A1/es active Pending
- 2004-03-31 PE PE2004000340A patent/PE20050013A1/es not_active Application Discontinuation
-
2005
- 2005-07-27 ZA ZA200506019A patent/ZA200506019B/en unknown
- 2005-09-30 HR HR20050871A patent/HRP20050871A2/xx not_active Application Discontinuation
- 2005-09-30 EC EC2005006065A patent/ECSP056065A/es unknown
- 2005-10-28 CO CO05110321A patent/CO5640152A2/es not_active Application Discontinuation
- 2005-10-31 NO NO20055057A patent/NO20055057L/no not_active Application Discontinuation
-
2006
- 2006-10-26 HK HK06111837A patent/HK1091130A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MXPA05010338A (es) | 2005-11-17 |
US7157424B2 (en) | 2007-01-02 |
KR20050108420A (ko) | 2005-11-16 |
HK1091130A1 (en) | 2007-01-12 |
UA81028C2 (en) | 2007-11-26 |
UY28250A1 (es) | 2004-11-30 |
AU2004231538A1 (en) | 2004-11-04 |
TW200505484A (en) | 2005-02-16 |
CN100363055C (zh) | 2008-01-23 |
CA2520886A1 (en) | 2004-11-04 |
NZ543250A (en) | 2008-12-24 |
HRP20050871A2 (en) | 2006-10-31 |
NO20055057L (no) | 2005-10-31 |
AR043795A1 (es) | 2005-08-10 |
ZA200506019B (en) | 2006-07-26 |
EP1613353A1 (en) | 2006-01-11 |
WO2004093915A1 (en) | 2004-11-04 |
BRPI0409068A (pt) | 2006-03-28 |
EA010013B1 (ru) | 2008-06-30 |
CO5640152A2 (es) | 2006-05-31 |
ECSP056065A (es) | 2006-01-27 |
JP2006522017A (ja) | 2006-09-28 |
US20040229776A1 (en) | 2004-11-18 |
RS20050741A (en) | 2007-06-04 |
CN1767856A (zh) | 2006-05-03 |
EA200501532A1 (ru) | 2006-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20050013A1 (es) | Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
CL2004000076A1 (es) | Compuestos derivados de indol, inhibidores de polimerasa, sales; composicion farmaceutica que los comprende; procedimiento de preparacion de dichos compuestos; compuestos intermediarios; y uso del compuesto para tratar una infeccion causada por el vi | |
PE20090995A1 (es) | Derivados indolicos 2,3-sustituidos como inhibidores del virus de la hepatitis c (vhc) | |
PE20091237A1 (es) | Derivados de pirrolidina como moduladores de serina proteasas | |
CO6251271A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
PA8580301A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
PE20060381A1 (es) | Analogos de dipeptidos inhibidores de la hepatitis c | |
PE20061298A1 (es) | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c | |
PE20021004A1 (es) | Derivados de piperidina como inhibidores de la ccr5 | |
AR033295A1 (es) | Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica | |
PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
PE20051150A1 (es) | Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c | |
AR038823A1 (es) | Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
AR074608A1 (es) | Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas | |
CO5200848A1 (es) | Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales | |
ECSP077171A (es) | Inhibidores de polimerasa viral | |
DOP2010000046A (es) | Compuestos de biciclolactama sustituida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |